Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue

Mol Cell Endocrinol. 2009 Jan 15;297(1-2):137-40. doi: 10.1016/j.mce.2008.11.018. Epub 2008 Nov 25.

Abstract

Liraglutide, a human glucagon-like peptide 1 (GLP-1) analogue with high homology to native GLP-1, has structural modifications sufficient to amend pharmacokinetics for once-daily administration without compromising biological activity. Data from large, controlled, clinical studies have confirmed the therapeutic profile of liraglutide, with robust reductions in HbA(1c), low risk of hypoglycaemia and clinically relevant reductions in body weight and systolic blood pressure.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Amino Acid Sequence
  • Clinical Trials as Topic
  • Drug Administration Schedule
  • Glucagon-Like Peptide 1 / administration & dosage
  • Glucagon-Like Peptide 1 / analogs & derivatives*
  • Glucagon-Like Peptide 1 / chemistry
  • Glucagon-Like Peptide 1 / pharmacology
  • Humans
  • Liraglutide
  • Molecular Sequence Data

Substances

  • Liraglutide
  • Glucagon-Like Peptide 1